ABBOTT INDIA LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: Private

Established: 1888-01-01

Employees: 73K

Market Cap: $7.5B

Website: http://www.abbott.com

Clinical Trials

Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS)

Completed

Conditions: Advanced Prostate Cancer
Lower Urinary Tract Symptoms

Interventions: Drug: Leuprolide acetate Depot Susp. 11.25 mg (Poland), 3.75 mg (Ukraine)

First Posted Date: 2010-03-02

Last Posted Date: 2012-01-16

Lead Sponsor: Abbott

Target Recruit Count: 729

Registration Number: NCT01078545

Locations: 🇵🇱
Site Reference ID/Investigator# 30988, Siemianowice Slaskie, Poland
🇵🇱
Site Reference ID/Investigator# 31031, Jastrzebie Zdroj, Poland
🇵🇱
Site Reference ID/Investigator# 31076, Belchatow, Poland

and more 140 locations

Safety and Effectiveness and Effect on Quality of Life and Work Productivity of Humira in Patients With Psoriatic Arthritis in Clinical Routine

Withdrawn

Conditions: Psoriatic Arthritis

Interventions: Biological: adalimumab (Humira)

First Posted Date: 2010-03-02

Last Posted Date: 2012-08-10

Lead Sponsor: Abbott

Registration Number: NCT01078610

Cost Utility Analyses of Adalimumab Treatment in Patients With Rheumatoid Arthritis (RA)

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2010-03-02

Last Posted Date: 2011-08-11

Lead Sponsor: Abbott

Target Recruit Count: 124

Registration Number: NCT01078116

Locations: 🇬🇷
Site Reference ID/Investigator# 32069, Athens, Greece
🇬🇷
Site Reference ID/Investigator# 32071, Crete, Greece
🇬🇷
Site Reference ID/Investigator# 32073, Larissa, Greece

and more 7 locations

Safety and Effectiveness of Adalimumab in Patients Diagnosed With Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis

Interventions: Biological: adalimumab (HUMIRA®)

First Posted Date: 2010-03-02

Last Posted Date: 2011-10-28

Lead Sponsor: Abbott

Target Recruit Count: 705

Registration Number: NCT01078571

Locations: 🇪🇸
Site Reference ID/Investigator# 28607, Ferrol, Spain
🇪🇸
Site Reference ID/Investigator# 29061, Algeciras, Spain
🇪🇸
Site Reference ID/Investigator# 29714, A Coruna, Spain

and more 37 locations

Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA

Completed

Conditions: Premature Infants

First Posted Date: 2010-03-01

Last Posted Date: 2012-08-21

Lead Sponsor: Abbott

Target Recruit Count: 124

Registration Number: NCT01077271

Locations: 🇦🇹
Site Reference ID/Investigator# 40440, Schorfling, Austria
🇦🇹
Site Reference ID/Investigator# 27765, Scheibbs, Austria
🇦🇹
Site Reference ID/Investigator# 30850, St Polten, Austria

and more 42 locations

Drug Use Investigation of Kaletra

Completed

Conditions: Human Immunodeficiency Virus

Interventions: Drug: Lopinavir/ritonavir (Kaletra)

First Posted Date: 2010-02-26

Last Posted Date: 2012-03-01

Lead Sponsor: Abbott

Target Recruit Count: 1184

Registration Number: NCT01076972

Locations: 🇯🇵
Site Reference ID/Investigator# 36637, Tokyo, Japan
🇯🇵
Site Reference ID/Investigator# 36623, Miyagi, Japan
🇯🇵
Site Reference ID/Investigator# 36630, Tokyo, Japan

and more 26 locations

Recovery Time in Thai Patients With Upper or Lower Respiratory Tract Infections Treated With Klacid MR

Completed

Conditions: Respiratory Tract Infection

Interventions: Drug: Clarithromycin (Klacid® MR)

First Posted Date: 2010-02-26

Last Posted Date: 2011-07-12

Lead Sponsor: Abbott

Target Recruit Count: 760

Registration Number: NCT01076153

Locations: 🇹🇭
Site Reference ID/Investigator# 27448, Bangkok, Thailand
🇹🇭
Site Reference ID/Investigator# 27445, Bangkok, Thailand
🇹🇭
Site Reference ID/Investigator# 27451, Bangkok, Thailand

and more 23 locations

Recovery Time in Children With Lower Respiratory Tract Infections Treated With Klacid® Granules for Oral Suspension.

Completed

Conditions: Lower Respiratory Tract Infection

Interventions: Drug: clarithromycin (Klacid) granules for oral suspension

First Posted Date: 2010-02-26

Last Posted Date: 2011-04-11

Lead Sponsor: Abbott

Target Recruit Count: 337

Registration Number: NCT01076166

Locations: 🇹🇭
Site Reference ID/Investigator# 27425, Bangkok, Thailand
🇹🇭
Site Reference ID/Investigator# 27423, Bangkok, Thailand
🇹🇭
Site Reference ID/Investigator# 27441, Nong khai, Thailand

and more 13 locations

Special Investigation of Kaletra in Pregnant Women

Completed

Conditions: Human Immunodeficiency Virus

Interventions: Drug: Lopinavir/ritonavir (Kaletra)

First Posted Date: 2010-02-26

Last Posted Date: 2012-01-18

Lead Sponsor: Abbott

Target Recruit Count: 24

Registration Number: NCT01076985

Locations: 🇯🇵
Site Reference ID/Investigator# 35862, Aichi, Japan
🇯🇵
Site Reference ID/Investigator# 35864, Osaka, Japan
🇯🇵
Site Reference ID/Investigator# 35863, Okayama, Japan

and more 2 locations

Drug Use Investigation for Humira® - All Patient Investigation for Rheumatoid Arthritis

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2010-02-26

Last Posted Date: 2012-08-28

Lead Sponsor: Abbott

Target Recruit Count: 7972

Registration Number: NCT01076959

Locations: 🇯🇵
Site Reference ID/Investigator# 42780, Miyagi, Japan
🇯🇵
Site Reference ID/Investigator# 58552, Miyagi, Japan
🇯🇵
Site Reference ID/Investigator# 39314, Miyagi, Japan

and more 1720 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy